Bill And Melinda Gates Foundation Bill And Melinda Gates Foundation [Member] Bill And Melinda Gates Foundation [Member] Document Type Document Type Other income (expense) Other Nonoperating Income (Expense) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Related Party Related Party [Axis] Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Other Current Assets Other Current Assets [Member] Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Warrant exercises, gross Proceeds from Warrant Exercises Licensing Agreements Licensing Agreements [Member] Statistical Measurement Statistical Measurement [Domain] Liabilities and stockholders’ equity (deficit) Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Additional potential grant funding Additional Potential Funding Related To Grant Award Additional Potential Funding Related To Grant Award Warrants exercised (in shares) Number Of Common Stock Warrants Exercised Number of common stock warrants exercised. License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended and Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Milestone payments, contingent amount Milestone Payments Contingent Amount Milestone payments, contingent amount. Loss from operations Operating Income (Loss) Total current liabilities Liabilities, Current National Institutes of Health National Institutes Of Health [Member] National Institutes Of Health [Member] Hammock Pharmaceuticals, Inc Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Commitments and contingencies (Note 8) Commitments and Contingencies Assets Assets [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Entity Address, State or Province Entity Address, State or Province Cash paid for measurement of operating lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Right of use asset Operating Lease, Right-of-Use Asset Potential annual license maintenance fee, payments in year one Potential Annual License Maintenance Fee, Payments In Year One Potential Annual License Maintenance Fee, Payments In Year One 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Gross proceeds from offering of common stock and warrants Gross Proceeds From Offering Of Common Stock And Warrants Gross Proceeds From Offering Of Common Stock And Warrants Health Care Trust Fund Health Care Trust Fund [Axis] Exchange cap (in shares) Common Stock, Exchange Cap Common Stock, Exchange Cap Total operating expenses Operating Expenses Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Cash and cash equivalents Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Warrant, exercise price, decrease (in usd per share) Warrant, Exercise Price, Decrease Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Revenue from grant for notice of award Revenue from Contract with Customer, Excluding Assessed Tax Regular purchase, common stock issuable (in shares) (up to) Regular Repurchase, Common Stock Issuable Regular Repurchase, Common Stock Issuable Measurement Frequency [Domain] Measurement Frequency [Domain] Closing price of the Company's common stock (in usd per share) Share Price Private Dare Private Dare [Member] Private Dare. Business Acquisition Business Acquisition [Axis] Statement [Line Items] Statement [Line Items] Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Warrants Expiring on December 1, 2021 Warrants Expiring On December One Two Thousand Twenty One [Member] Warrants expiring on december one two thousand twenty one. Class of Stock [Domain] Class of Stock [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Contingent consideration, net of current portion Business Combination, Contingent Consideration, Liability, Noncurrent Statement [Table] Statement [Table] Statistical Measurement Statistical Measurement [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Business Combinations [Abstract] Business Combinations [Abstract] Grant, DARE-FRT1 Grant, DARE-FRT1 [Member] Grant, DARE-FRT1 Loss per common share - basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Entity Small Business Entity Small Business Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants. Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Prepaid expenses Prepaid Expense, Current Aggregate net proceeds on sales of shares of common stock Proceeds from Issuance of Common Stock Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Amendment Flag Amendment Flag Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Warrants Expiring on December 6, 2021 Warrants Expiring On December Six Two Thousand Twenty One [Member] Warrants expiring on december six two thousand twenty one. Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Business acquisition transaction value Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Options to purchase number of outstanding shares of common stock Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Aggregate commission rate Percentage Of Aggregate Commission Percentage of aggregate commission. Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Related Party Related Party [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Business Combination Reverse Merger [Line Items] Business Combination Reverse Merger [Line Items] Business combination reverse merger. Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Subsequent Events Subsequent Events [Text Block] Milestone Payments Milestone Payments Milestone Payments Renewal term of operating lease Lessee, Operating Lease, Renewal Term Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Income Statement Location Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location Income Statement Location [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] ATM Sales Agreement At The Market Sales Agreement [Member] At The Market Sales Agreement [Member] Contingent consideration, net of current portion Asset Acquisition, Contingent Consideration, Noncurrent Asset Acquisition, Contingent Consideration, Noncurrent Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Other non-current assets Other Assets, Noncurrent Plan Name Plan Name [Axis] Exchange cap, percentage Common Stock, Exchange Cap, Percentage Common Stock, Exchange Cap, Percentage Issuance of common stock Stock Issued During Period, Value, New Issues Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total assets Assets Title of 12(b) Security Title of 12(b) Security Weighted-average fair value of options granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value License agreement termination period due to performance failure License Agreement Termination Period Due To Performance Failure License agreement, termination period due to performance failure. Subsequent Event Type Subsequent Event Type [Axis] Antidilutive Securities Antidilutive Securities [Axis] Class of Warrant or Right Class of Warrant or Right [Axis] Proceeds received in public offering, net of underwriting discounts and offering expenses Sale of Stock, Consideration Received on Transaction Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Proceeds from issuance of note payable Proceeds from Notes Payable Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less: Difference between future minimum lease payments and discounted operating lease liabilities Lessee, Operating Lease, Liability, Undiscounted Excess Amount Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Net loss to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Legal, accounting and other fees related to Purchase Agreement Deferred Offering Costs Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accounts payable Increase (Decrease) in Accounts Payable Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Underwriters overallotment option to purchase additional shares of common stock and warrants period Underwriters Option To Purchase Additional Shares Of Common Stock Period Underwriters option to purchase additional shares of common stock period. Additional paid-in capital Additional Paid-in Capital [Member] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Accrued expenses Increase (Decrease) in Accrued Liabilities Non-cash adjustments reconciling net loss to operating cash flows: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Offering expenses Offering Expenses Offering Expenses Loan under Paycheck Protection Program Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Common stock, shares outstanding (in shares) Common stock, shares outstanding Common Stock, Shares, Outstanding Research and development Research and Development Expense Subsequent Event Subsequent Event [Member] Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Weighted Average Amortization Period Weighted Average Amortization Period Weighted Average Amortization Period Income Statement [Abstract] Income Statement [Abstract] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Deemed dividend from trigger of down round provision feature Deemed dividend from trigger of down round provision feature Deemed dividend from trigger of down round provision Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount Lease liabilities long-term Operating Lease, Liability, Noncurrent Underwritten Offering Over-Allotment Option [Member] Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Current assets Assets, Current [Abstract] Upon Delivery of Six Month Batch Development Not Later Than Eleven Months Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Milestone payments Research And Development Milestone Payment Research and development milestone payment. Grant, Ovaprene Grant, Ovaprene [Member] Grant, Ovaprene 2015 Stock Incentive Plan Two Thousand And Fifteen Stock Incentive Plan [Member] Two Thousand And Fifteen Stock Incentive Plan [Member] Deferred grant funding Deferred Grant Funding Current Deferred Grant Funding Current Counterparty Name [Domain] Counterparty Name [Domain] Legal Entity Legal Entity [Axis] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Document Period End Date Document Period End Date Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Contingent consideration, liability Business Combination, Contingent Consideration, Liability Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Issuance cost on equity line paid in common stock (in shares) Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Prepaid expenses Increase (Decrease) in Prepaid Expense Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Entity Entity [Domain] License fees License fee License Fee License Fee Cover [Abstract] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Development and Option Agreement Development And Option Agreement [Member] Development And Option Agreement [Member] Upfront license fee paid Upfront License Fee Paid Upfront License Fee Paid Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Deferred license revenue Increase (Decrease) in Contract with Customer, Liability Leased Properties Lessee, Operating Leases [Text Block] Commencement period for stage two upon achievement of stage one Commencement Period For Stage Two Upon Achievement Of Stage One Commencement Period For Stage Two Upon Achievement Of Stage One Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Proceeds from the exercise of stock options Proceeds from Issuance or Sale of Equity Equity Components [Axis] Equity Components [Axis] Restricted Stock Restricted Stock [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Receivables [Abstract] Receivables [Abstract] Minimum Minimum [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Current portion of lease liabilities Operating Lease, Liability, Current Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Square footage of office space Net Rentable Area Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Obligation to purchase common stock Purchase Obligation Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-based Payment Arrangement, Option, Activity [Table Text Block] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Additional paid-in capital Additional Paid in Capital, Common Stock Health Care Trust Fund, Name Health Care Trust Fund, Name [Domain] Entity Registrant Name Entity Registrant Name Subsequent Event Type Subsequent Event Type [Domain] Class of Warrant or Right Class of Warrant or Right [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Grant Grant [Member] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Adare Adare Pharmaceuticals [Member] Adare Pharmaceuticals [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Research and Development Expense Research and development Research and Development Expense [Member] Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Sale of Stock Sale of Stock [Axis] Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Entity Address, Postal Zip Code Entity Address, Postal Zip Code Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Document Transition Report Document Transition Report Current portion of contingent consideration Business Combination, Contingent Consideration, Liability, Current Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Warrants Warrant [Member] Shares underlying outstanding warrants (in shares) Class of Warrant or Right, Outstanding Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Level 2 Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Canceled/forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Equity [Abstract] Equity [Abstract] General and administrative General and Administrative Expense [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Annual percentage increase in outstanding number of common stock Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Subsequent Event [Line Items] Subsequent Event [Line Items] Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Certain clinical and regulatory development milestone payments License Agreement Notice Period Of Termination License Agreement Notice Period Of Termination Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Number of operating segments Number of Operating Segments Entity File Number Entity File Number Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Expiration Date Class Of Warrant Or Rights Warrants Expiration Date Class of warrant or rights warrants expiration date. Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. Issuance of common stock from the exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Regular purchase, common stock issuable, increase amount (in shares) Regular Purchase, Common Stock Issuable, Increase Amount Regular Purchase, Common Stock Issuable, Increase Amount Stock-based compensation expense Share-based Payment Arrangement, Expense Increase in number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Counterparty Name [Axis] Counterparty Name [Axis] Common stock, $0.0001 par value; 120,000,000 shares authorized; 33,602,516 and 19,683,401 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Unamortized stock-based compensation expense Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Document Fiscal Year Focus Document Fiscal Year Focus Unamortized costs related to legal, accounting, and other fees Deferred Offering Costs, Unamortized Portion Deferred Offering Costs, Unamortized Portion Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Entity Current Reporting Status Entity Current Reporting Status Stock sale price (in usd per share) Sale of Stock, Price Per Share Related Party Transaction [Axis] Related Party Transaction [Axis] Subsequent Event [Table] Subsequent Event [Table] Business combination shares issued (in usd per share) Business Acquisition, Share Price License agreement termination periodic discontinued sale of product License Agreement Termination Periodic Discontinued Sale Of Product License Agreement Termination Periodic Discontinued Sale Of Product Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current Other non-current assets Increase Decrease In Other Non Current Assets And Deferred Charges Increase decrease in other non-current assets and deferred charges. License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Purchase Agreement Purchase Agreement [Member] Purchase Agreement Upon Signing of Development and Option Agreement Upon Signing Of Development And Option Agreement [Member] Upon Signing Of Development And Option Agreement [Member] Schedule Of Business Combination Reverse Merger [Table] Schedule Of Business Combination Reverse Merger [Table] Schedule of business combination reverse merger. Total operating lease liabilities Operating Lease, Liability Project [Domain] Project [Domain] Total stockholders' equity (deficit) Beginning balance Ending balance Stockholders' Equity Attributable to Parent Offering expenses Payments of Stock Issuance Costs Total liabilities and stockholders' equity (deficit) Liabilities and Equity Common stock issued to microchips capital stock holders (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Address, City or Town Entity Address, City or Town Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Grants receivable Grants Receivable Non-cash lease expenses Operating Lease, Cost General and administrative General and Administrative Expense Type of Adoption [Domain] Accounting Standards Update [Domain] Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Issuance cost on equity paid in common stock Issuance Cost On Equity Paid In Common Stock Issuance Cost On Equity Paid In Common Stock Notes payable including accrued interest Notes Payable, Current, Plus Accrued Interest Notes Payable, Current, Plus Accrued Interest License fee to be paid upon contingency License Fee, To Be Paid Upon Contingency License Fee, To Be Paid Upon Contingency Equity Component [Domain] Equity Component [Domain] Percentage of rights to inventions by employees under license agreement Percentage Of Rights To Inventions By Employees Under License Agreement Percentage of rights to inventions by employees under license agreement. Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' equity. Property and equipment, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Other receivables Increase (Decrease) in Other Receivables Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Remainder of 2020 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Stockholders Equity [Table] Stockholders Equity [Table] Stockholders' equity. Leases [Abstract] Leases [Abstract] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses Operating Expenses [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Stock registered for resale (in shares) Sale of Stock, Maximum Amount Registered Sale of Stock, Maximum Amount Registered Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stockholders' equity (deficit) Stockholders' Equity Attributable to Parent [Abstract] MilanaPharm MilanaPharm [Member] MilanaPharm [Member] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Cash and cash equivalents Convertible Debt At-the-Market Equity Offerings At-the-Market Equity Offerings [Member] At-the-Market Equity Offerings Deferred license revenue Contract with Customer, Liability, Noncurrent Warrants Expiring on February 15, 2023 Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Other receivables Other Receivables, Net, Current Supplemental disclosure of non-cash operating and financing activities: Supplemental Cash Flow Information [Abstract] Underwriters option to purchase additional shares Underwriters Option To Purchase Additional Shares Underwriters option to purchase additional shares. Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Upon Completion of Fifty Percent Development Not Later Than Six Months Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Entity Filer Category Entity Filer Category Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common stock Common stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Incremental borrowing rate Lessee, Operating Lease, Discount Rate Issuance of common stock (in shares) Common stock, shares issued and sold Stock Issued During Period, Shares, New Issues Grant Award Grant Award [Text Block] Grant Award [Text Block] Note annual interest rate Debt Instrument, Interest Rate, Stated Percentage Stock options exercised (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Acquisition Business Combination Disclosure [Text Block] Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Employee Stock Option Stock options Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Events [Abstract] Subsequent Events [Abstract] Canceled/forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Sale of Stock Sale of Stock [Domain] Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Plan Name Plan Name [Domain] Organization and Description of the Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Class of Stock [Axis] Class of Stock [Axis] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Accrued expenses Accrued Liabilities, Current Local Phone Number Local Phone Number Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Lincoln Park Lincoln Park [Member] Lincoln Park Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Depreciation Depreciation Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Project [Axis] Project [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Award Type Award Type [Axis] Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate. Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Accumulated deficit Retained Earnings [Member] Issuance cost on equity line paid in common stock Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Public Stock Offering Public Stock Offering [Member] Public Stock Offering [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Equity Award Award Type [Domain] ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Trading Symbol Trading Symbol Exercisable (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Note payable Notes Payable, Current Net Loss Per Share Earnings Per Share [Text Block] Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Amount awarded for grant Proceeds From Award Of Grant Proceeds From Award Of Grant Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Regular purchase, common stock issuable, maximum amount (in shares) Regular Purchase, Common Stock Issuable, Maximum Amount Regular Purchase, Common Stock Issuable, Maximum Amount